Multiple Myeloma · Active Clinical Trials
As of 2026-09-04, the full China registry snapshot contains 70 active multiple myeloma interventional trials across 31 provincial-level regions and 338 China study centres, see landscape index. The list below provides peer-reviewed published English translations and can be filtered by modality, target, phase, and province.
Notice for International Patients
These records are provided for research-information purposes. An English summary does not mean that the clinical trial accepts international patients. Eligibility, language requirements, residence requirements and long-term follow-up must be confirmed directly with the clinical trial team. Original registry filings remain in Chinese. For a non-trial route, see independent guide to CAR-T in China.
Trial Decision Guides
All trial FAQsNotice for Patients on Stable Therapy:If your current regimen is effective, do not discontinue standard treatment. Clinical trial matching is recommended upon documented disease progression.
Showing all 70 active clinical trials
A Phase III, Randomized Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy (Including an Anti-CD38 Antibody and Lenalidomide)
Locations & Centers
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)、The First Affiliated Hospital, Zhejiang University School of Medicine、Sun Yat-sen University Cancer Center 等 222 家
Target / Modality
Trispecific antibody targeting BCMA, GPRC5D, and CD3
A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone Versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 78 家
Target / Modality
Novel monoclonal antibody targeting CD38
A Phase I Study of In Vivo CAR-T Therapy for Advanced Malignant Tumors (Multiple Myeloma, Lymphoma, Leukemia, Solid Tumors)
Locations & Centers
Cancer Hospital, Chinese Academy of Medical Sciences
Target / Modality
In situ (in vivo) CAR-T cell therapy targeting multiple targets including BCMA/GPRC5D/DLL3/FcRH5
A Randomized, Double-Blind, Parallel-Controlled Study Comparing the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of JY43 and Darzalex® in Healthy Male Participants
Locations & Centers
Beijing Gobroad Hospital、PKU Healthcare Luzhong Hospital
Target / Modality
Daratumumab biosimilar (monoclonal antibody)
A Phase II, open-label, single-arm, multicenter clinical study evaluating the efficacy and safety of BCMA-targeted chimeric antigen receptor T-cell injection (CART-BCMA) in patients with relapsed/refractory multiple myeloma (RRMM)
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Beijing Jishuitan Hospital 等 25 家
Target / Modality
BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy
A Phase I Clinical Study of CBG002 CAR-T Cell Injection in Patients with Relapsed or Refractory Multiple Myeloma
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Sun Yat-sen University Cancer Center
Target / Modality
BCMA-targeting CAR-T cell therapy
A Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of CR-2011 in Relapsed/Refractory Multiple Myeloma
Locations & Centers
Cancer Hospital Chinese Academy of Medical Sciences
Target / Modality
In vivo chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA (based on mRNA-LNP technology)
A Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HP-001 Capsules Combined with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Locations & Centers
West China Hospital, Sichuan University、Henan Cancer Hospital、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences 等 20 家
Target / Modality
Small-molecule chemical drug
An Early Exploratory Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of BCMA/GPRC5D Dual-Targeted Allogeneic Universal CAR-T Cell Injection (DQ1001) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Locations & Centers
Zhongshan Hospital, Xiamen University
Target / Modality
Allogeneic universal CAR-T targeting BCMA/GPRC5D
A Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of 6MW5311 in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, and Multiple Myeloma
Locations & Centers
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、The First Affiliated Hospital, Zhejiang University School of Medicine 等 8 家
Target / Modality
LILRB4 and CD3 bispecific antibody
A Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Locations & Centers
Peking University People's Hospital、Tongji Medical College of Huazhong University of Science and Technology、Qilu Hospital of Shandong University 等 37 家
Target / Modality
Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])
A Phase I/II, Multicenter, Open-Label Study of IBI3003 in Participants with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Zhongshan Hospital, Fudan University、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、The First Affiliated Hospital of Xi'an Jiaotong University 等 23 家
Target / Modality
Trispecific antibody targeting GPRC5D, BCMA, and CD3
An Early Exploratory Clinical Study of the Safety and Efficacy of KSVCBD Injection in the Treatment of CD19- and/or BCMA-Positive B-Cell Malignancies
Locations & Centers
Chinese PLA General Hospital (301 Hospital)
Target / Modality
CD19, BCMA
An Open-Label, Multicenter Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of OriCAR-017 in Participants with Relapsed/Refractory Multiple Myeloma (MERCURY)
Locations & Centers
The First Affiliated Hospital, Zhejiang University School of Medicine、Shanghai Tongji Hospital、Jiangsu Province Hospital 等 8 家
Target / Modality
GPRC5D-targeted CAR-T
A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC Versus DARZALEX FASPRO Combined with Lenalidomide-Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Locations & Centers
Zhongshan Hospital Affiliated to Fudan University、Peking University Third Hospital、Guangzhou First People's Hospital 等 66 家
Target / Modality
Recombinant fully human monoclonal antibody targeting CD38
A Multicenter, Open-Label Phase II Study Evaluating QLS4131 for Injection in Combination Therapy for the Treatment of Malignant Plasma Cell Neoplasms
Locations & Centers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Henan Cancer Hospital 等 39 家
Target / Modality
Trispecific antibody targeting BCMA, CD3, and GPRC5D
A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Study of IBI3003 Versus Investigator's Choice of Regimen (DPd or PVd) on the Efficacy and Safety in Participants with Relapsed or Refractory Multiple Myeloma
Locations & Centers
Zhongshan Hospital, Fudan University、The First Affiliated Hospital, Zhejiang University School of Medicine、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology 等 45 家
Target / Modality
GPRC5D/BCMA/CD3 trispecific antibody
In Vivo-Generated PICX Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Locations & Centers
The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Target / Modality
BCMA/CD70 CAR-T
A Phase I, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HL17 in Participants with Relapsed or Refractory Multiple Myeloma
Locations & Centers
PKU Healthcare Luzhong Hospital
Target / Modality
Recombinant anti-BCMA and CD3 bispecific antibody injection